Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Drug Policy / Regulatory

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) is implementing new safety measures for opioid pain...

Company Drug

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial

Fineline Cube Aug 4, 2025

China-based Luye Pharma Group (HKG: 2186) announced on August 3, 2025, that its self-developed Class...

Company Deals

AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis

Fineline Cube Aug 1, 2025

China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany’s Dr. Falk Pharma GmbH to...

Company Deals

Grand Pharma Partners with IRE EliT to Distribute 68Ge/68Ga Generators in China

Fineline Cube Aug 1, 2025

On July 31, 2025, China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced a strategic collaboration...

Company Drug

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Fineline Cube Aug 1, 2025

Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced that its in-licensed programmed-death ligand 1 (PD-L1) monoclonal...

Company Deals

BrightGene and CR Sanjiu Collaborate on BGM0504 Injection Development and Commercialization

Fineline Cube Aug 1, 2025

China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) and its affiliated companies announced a collaboration...

Company

AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth

Fineline Cube Aug 1, 2025

US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...

Company

BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook

Fineline Cube Aug 1, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues...

Policy / Regulatory

China’s NHSA Issues Rules for Instant Settlement of Medical Insurance Funds

Fineline Cube Aug 1, 2025

China’s National Healthcare Security Administration (NHSA) has issued the “Interim Administrative Rules for Instant Settlement...

Company Deals

Hybio and BrightGene Partner on Peptide Raw Material Supply for Global Drug Commercialization

Fineline Cube Aug 1, 2025

China-based Hybio Pharmaceutical Co., Ltd. (SHE: 300199) and China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA:...

Company Drug

BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia

Fineline Cube Aug 1, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced on July 31, 2025,...

Company Drug

Neurodawn’s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection

Fineline Cube Aug 1, 2025

China-based Neurodawn Pharmaceutical Co., Ltd.’s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan...

Policy / Regulatory

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services

Fineline Cube Aug 1, 2025

On July 31, 2025, China’s National Medical Products Administration (NMPA) commenced soliciting public comments on...

Company Drug

Haisco’s Ciprofol NDA Accepted by FDA: A Milestone for Chinese Anesthesia Innovation

Fineline Cube Aug 1, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that the New Drug Application (NDA)...

Company Drug

AstraZeneca’s Ultomiris Gains NMPA Approval for Neuromyelitis Optica Spectrum Disorder

Fineline Cube Aug 1, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Chipscreen’s Next-Gen Brain-Penetrant Aurora B Inhibitor CS231295 Gains FDA Clearance for Advanced Solid Tumors

Fineline Cube Aug 1, 2025

On July 31, 2025, the investigational new drug (IND) application for Shenzhen Chipscreen Biosciences Co.,...

Company Drug

Hengrui Receives Clinical Clearance for HRS-5041 in Prostate Cancer Treatment

Fineline Cube Aug 1, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance from...

Company Deals

Porton Advanced and Cellstore Partner to Optimize Cell Therapy Drug Cryopreservation

Fineline Cube Jul 31, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. and Cellstore announced today...

Company Deals

ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration

Fineline Cube Jul 31, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced today that it has received a...

Company Deals

Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million

Fineline Cube Jul 31, 2025

China-based Luoxin Pharmaceutical Group Co., Ltd. (SHE: 002793) announced that its subsidiary, Shandong Luoxin Pharmaceutical...

Posts pagination

1 … 54 55 56 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.